Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Ann M. Hanly Sells 2,711 Shares

Vir Biotechnology, Inc. (NASDAQ:VIRGet Free Report) EVP Ann M. Hanly sold 2,711 shares of Vir Biotechnology stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $10.05, for a total transaction of $27,245.55. Following the transaction, the executive vice president now owns 132,069 shares of the company’s stock, valued at $1,327,293.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Vir Biotechnology Stock Down 5.7 %

Vir Biotechnology stock traded down $0.58 during midday trading on Tuesday, hitting $9.62. 999,243 shares of the stock were exchanged, compared to its average volume of 1,092,915. Vir Biotechnology, Inc. has a 52-week low of $7.72 and a 52-week high of $27.48. The stock has a market capitalization of $1.30 billion, a price-to-earnings ratio of -2.10 and a beta of 0.41. The business’s 50-day moving average price is $10.20 and its 200-day moving average price is $9.66.

Vir Biotechnology (NASDAQ:VIRGet Free Report) last released its earnings results on Thursday, February 22nd. The company reported ($0.86) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.28. The firm had revenue of $16.80 million for the quarter, compared to analysts’ expectations of $11.18 million. Vir Biotechnology had a negative net margin of 713.69% and a negative return on equity of 34.92%. The company’s quarterly revenue was down 66.0% on a year-over-year basis. During the same period in the previous year, the company earned ($0.76) earnings per share. On average, sell-side analysts predict that Vir Biotechnology, Inc. will post -4.04 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $110.00 price objective on shares of Vir Biotechnology in a report on Friday, March 15th. JPMorgan Chase & Co. lifted their price objective on shares of Vir Biotechnology from $9.00 to $10.00 and gave the company a “neutral” rating in a report on Friday, February 23rd. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Vir Biotechnology currently has an average rating of “Moderate Buy” and an average price target of $34.38.

Get Our Latest Research Report on Vir Biotechnology

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VIR. Perceptive Advisors LLC boosted its stake in Vir Biotechnology by 1,277.2% in the second quarter. Perceptive Advisors LLC now owns 1,958,264 shares of the company’s stock valued at $48,036,000 after acquiring an additional 1,816,070 shares during the last quarter. Vanguard Group Inc. boosted its stake in Vir Biotechnology by 21.1% in the third quarter. Vanguard Group Inc. now owns 9,928,416 shares of the company’s stock valued at $191,420,000 after acquiring an additional 1,731,172 shares during the last quarter. State Street Corp boosted its stake in Vir Biotechnology by 65.9% in the first quarter. State Street Corp now owns 4,193,764 shares of the company’s stock valued at $107,864,000 after acquiring an additional 1,665,657 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Vir Biotechnology by 2,167.7% in the second quarter. Dimensional Fund Advisors LP now owns 1,022,739 shares of the company’s stock valued at $25,091,000 after acquiring an additional 977,639 shares during the last quarter. Finally, Norges Bank purchased a new position in Vir Biotechnology in the fourth quarter valued at about $18,440,000. 65.32% of the stock is currently owned by hedge funds and other institutional investors.

About Vir Biotechnology

(Get Free Report)

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand.

Featured Articles

Insider Buying and Selling by Quarter for Vir Biotechnology (NASDAQ:VIR)

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.